This work establishes a generalizable framework for mapping tumour-engaged immunity without knowledge of the underlying antigen in the transcriptome by demonstrating that clonal behaviour across space and time encodes tumour reactivity in the transcriptome.
Abstract
Tumour-targeting CD8⁺ T cells drive responses to every major form of cancer immunotherapy. Identifying them, however, remains an unsolved problem in solid tumours. The antigens they recognize are rarely defined and almost never shared between patients. We profiled 51,459 CD8+ T cells by paired single-cell RNA and T-cell receptor sequencing across 28 samples from 17 HPV-negative oral cancers spanning primary tumours, draining lymph nodes, metastases, and pembrolizumab-treated recurrences. We found that clonotypes that were expanded and shared across anatomical sites and timepoints were enriched within tumours and progressively selected over disease evolution and checkpoint blockade. Designating these shared-expanded clones as putative tumour-targeting cells, we trained a machine learning classifier that identifies them from transcriptome data alone. This 108-feature random forest signature recapitulated programmes of tumour reactivity and generalized to an integrated atlas of 89,318 CD8+ T cells from independent cohorts, showing progressive enrichment from normal to malignant tissue, and localized to tumour-proximal niches in spatial transcriptomics. By demonstrating that clonal behaviour across space and time encodes tumour reactivity in the transcriptome, this work establishes a generalizable framework for mapping tumour-engaged immunity without knowledge of the underlying antigen.
Immune checkpoint blockade has improved outcomes for patients with head and neck squamous cell carcinoma (HNSCC), but reliable biomarkers for predicting therapeutic response remain limited. Tumor-reactive T-cell states are increasingly recognized as critical determinants of antitumor immunity; however, progression-asso...
CD4+CD25+FOXP3+ regulatory T cells (Treg) are highly activated in tumors and promote disease progression. Specific, universal targeting of these effector Treg cells is limited by the lack of a conserved signature across human cancers and information on their origin. Here we combine analysis of single-cell RNA-sequencin...
J. Swatler, S. Puccio, Emanuele Voulaz et al.· Nature Communications· 0 citations
Glioblastoma (GBM) is the most common and aggressive primary brain tumour in adults, with a median survival of approximately 15 months despite multimodal treatment. The GBM tumour microenvironment is recognised as profoundly immunosuppressive, yet the role of B cell-mediated humoral immunity remains largely unexp...
Bo Sun, Aleema Iqbal, Safiyah Mohamed et al.· Neuro-Oncology· 0 citations
Introduction Tumor-reactive T cell receptors (TCRs) are promising candidates for the manufacturing of safe and effective adoptive TCR-T cell therapies, but their efficient identification remains a major challenge. We previously established an antigen-agnostic TCR-repertoire analysis workflow that prioritizes candidate...
V. Seitz, J. Franzen, K. Gennermann et al.· bioRxiv· 0 citations
Overall, tumor-invaded LNs and tumors coordinate the generation and maintenance of tumor-reactive CD4+ lineages, identifying highly plastic follicular T cells as therapeutic checkpoints to reinforce anti-tumor responses.
Jimena Tosello Boari, W. Richer, Y. Missolo-Koussou et al.· Nature Communications· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.